Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2017-06-19 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules for periodic reports by foreign issuers. It includes a press release about hosting a conference call on Phase III top-line results. The document length is short (1927 characters) and primarily serves as a notification of the press release and upcoming conference call, not the full transcript or detailed financial report. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information between annual reports. There is no detailed financial data or full conference call transcript included, only an announcement of the event and results. Therefore, this fits best under Regulatory Filings (RNS) as a general SEC filing and announcement, not a full earnings release or call transcript.
2017-06-19 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release announcement about the initiation of a Phase III study for a drug. The document is short (1919 characters) and primarily serves as a report of a press release rather than a detailed financial or operational report. Form 6-K filings are typically used for current reports by foreign private issuers and often contain announcements or updates rather than full reports. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-15 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release announcing successful Phase III top-line results for a drug, BEKINDA, for acute gastroenteritis. The document is short (1913 characters) and primarily serves as a regulatory announcement of clinical trial results rather than a full financial report or detailed management discussion. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information. This does not fit the definitions of Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or other detailed financial or governance reports. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-06-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The content includes a press release about promotion activities, and the document is short (1884 characters). It does not contain financial statements or detailed financial data. It is an informational report rather than a full financial report or earnings release. According to the rules, Form 6-K filings are generally considered Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about a presentation at the 2017 BIO International Convention. The document is short (1873 characters) and primarily serves as a regulatory filing to report a press release rather than containing detailed financial data or a full report. Form 6-K filings are typically used for current reports by foreign private issuers and are considered regulatory filings. Therefore, this document fits best under the Regulatory Filings (RNS) category.
2017-06-06 English
Regulatory Filings 2017
Regulatory Filings
2017-05-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.